← Leaderboards
Ramsey Hachem
Washington University
$6,763,198
Attributed
$19,786,185
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,786,185 · 7
By mechanism
U01$15,471,597 · 1
R34$2,175,415 · 2
R01$782,289 · 1
R61$655,076 · 1
R33$544,885 · 1
T32$156,923 · 1
Top collaborators
- Daniel Kreisel5 shared
- Joren C Madsen5 shared
- Derek E Byers3 shared
- Andrew Eric Gelman3 shared
- Charles Goss3 shared
- Howard J Huang3 shared
- Kenneth B. Schechtman3 shared
- Roger D Yusen2 shared
Most similar at Washington University
Same institution · by research overlap
- Joshua S Shimony$7,166,593
- Stuart C Sweet$14,692,756
- Eric Claude Leuthardt$7,214,894
- David D Tran$4,389,335
- Dmitriy A Yablonskiy$13,431,767
Others in their field
Top investigators on “Transplant Recipients”
- Leland H Hartwell · Fred Hutchinson Cancer Research Center$84,240,435
- Peter Scott Heeger · Case Western Reserve University$83,635,934
- Joren C Madsen · Massachusetts General Hospital$58,876,734
- Mary M Horowitz · Medical College Of Wisconsin$55,693,586
- Peter G Stock · University Of California San Francisco$39,243,787
- Leslie S Kean · Emory University$39,217,487
Research focus
Transplant RecipientsFunctional DisorderChronicLung TransplantationPreventAcuteLung AllograftCessation Of LifeLungFutureDesignClinical TrialsPrimary EndpointPlacebosTransplantationAllograft RejectionAllograftingSignal TransductionImproved OutcomeRisk FactorsKidneySecondary EndpointStandard Of CareLymphocyte
Grant awards (15)
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab$3,310,755
U01 · FY2025 · AI
Incorporating Donor Lung CT Images into Machine Learning Models to Predict Severe Primary Graft Dysfunction after Lung Transplantation$782,289
R01 · FY2025 · HL · contact PI
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$544,885
R33 · FY2025 · HL · contact PI
Multidisciplinary Pulmonary and Critical Care Training Program$156,923
T32 · FY2025 · HL · contact PI
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab$3,256,574
U01 · FY2024 · AI
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$283,671
R61 · FY2024 · HL · contact PI
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab$3,130,730
U01 · FY2023 · AI
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$371,405
R61 · FY2023 · HL · contact PI
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab$3,063,266
U01 · FY2022 · AI
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab$2,710,272
U01 · FY2021 · AI
A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression in Lung Transplantation$237,979
R34 · FY2020 · HL · contact PI
A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression in Lung Transplantation$237,524
R34 · FY2019 · HL · contact PI
A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression in Lung Transplantation$250,034
R34 · FY2018 · HL · contact PI
TREATMENT OF ANTI-HLA ANTIBODIES TO PREVENT BOS AFTER LUNG TRANSPLANTATION$691,367
R34 · FY2011 · HL
TREATMENT OF ANTI-HLA ANTIBODIES TO PREVENT BOS AFTER LUNG TRANSPLANTATION$758,511
R34 · FY2010 · HL